East Midlands-based biotechnology company N4 Pharma has formed a new senior leadership team featuring consultants in drug ...

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical ...

Kirkland & Ellis announced the hire Wednesday of a three-partner M&A team from Skadden, Arps, Slate, Meagher & Flom, on the ...

I n her State of the City address in March, Mayor Michelle Wu spoke about her then-2-month-old daughter. The world she ...

As venture funding becomes concentrated in fewer, larger rounds, a biotech with operations in Newton has secured a ...

Strive Asset Management has raised $750 million to pursue the strategy while Ramaswamy runs to be Ohio’s governor.

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

A Boston-based neurotech, armed with $500,000 in Rhode Island incentives, plans to establish a location in Providence.

Wilson's new company, Philadelphia-based Gemma Biotherapeutics, plans to start testing gene therapies in Brazil this year.

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future ...

Biogen and City Therapeutics are collaborating to develop select RNAi therapies in a $46 million partnership. City Therapeutics, a private biopharmaceutical company, will offer its RNAi-engineering ...